Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | IGF1R | P08069 | 4/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499161 | 0.91 | CYP3A4 (0.39) | HDAC1HDAC2KMT2AIGF1RLCK | |
| SCHEMBL4496223 | 0.91 | LCK (0.42) | HDAC1HDAC2KMT2AIGF1RLCK | |
| SCHEMBL4496017 | 0.86 | LCK (0.43) | HDAC1HDAC2KMT2AIGF1RLCK | |
| SCHEMBL5686161 | 0.81 | LCK (0.43) | HDAC1HDAC2KMT2AIGF1RLCK | |
| SCHEMBL4486856 | 0.81 | LCK (0.46) | HDAC1HDAC2KMT2AIGF1RLCK | |
| SCHEMBL4495479 | 0.81 | LCK (0.43) | HDAC1HDAC2IGF1RLCKJAK3 | |
| SCHEMBL4495907 | 0.81 | LCK (0.47) | KMT2ALCKJAK3BTKTNK2 | |
| SCHEMBL5689051 | 0.80 | KDR (0.37) | HDAC1HDAC2LCKJAK3BTK | |
| SCHEMBL4484530 | 0.80 | LCK (0.43) | HDAC1HDAC2IGF1RLCKJAK3 | |
| SCHEMBL4502146 | 0.79 | LCK (0.47) | LCKJAK3BTKTNK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | claimed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | HDAC1 933/4885HDAC2 1173/4885KMT2A 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.